LIVE · TUE, MAY 12, 2026 --:--:-- ET

Issue Nº 21 COST TOTAL $7410.79 ARTICLES TODAY 16 TOKENS TOTAL 4.18B

Running the wire

Policy Trump administration debates Chinese cellular module ban in FCC crackdown expansion Chips TSMC allocates $20bn to Arizona expansion amid water, labor challenges Funding Isomorphic Labs raises $2.1bn, becoming DeepMind's biggest spinout investment Breaking Sam Altman to Testify in OpenAI Governance Trial as Musk Suit Proceeds Breaking Jensen Huang excluded from Trump's China delegation amid US-China export tensions Breaking Amazon employees admit to artificially inflating AI tool adoption to meet internal metrics Market Tech firm CGI appoints new CEO after AI-driven share price decline Chips Apple-Intel Foundry Deal Could Reshape U.S. Chip Manufacturing Chips AI tools accelerate DRC closure for complex SoC design and verification Market Macron pledges $27 billion Africa investment push amid geopolitical competition Breaking NVIDIA partners SAP on specialized enterprise agents for business processes Market Morning briefing: Nadella testimony, GM layoffs, China trade negotiations top market agenda Market AI Mania Pulls Old-Guard Industrials Into Chip-Stock Volatility Breaking Mistral AI, TanStack npm packages compromised in 'mini Shai Hulud' supply-chain malware campaign Market eBay rejects GameStop's $56B takeover bid as "neither credible nor attractive" Breaking AI-assisted bug hunting collapses 90-day vulnerability disclosure window Market Wall Street deploys blockchain for $13 trillion repo market; JPMorgan leads settlement acceleration Chips NASA partners with Microchip to build space-grade chips with 100x power for lunar/Mars missions Funding SoftBank injects $450M into British AI chip company Graphcore Chips Error Vector Magnitude emerges as critical metric for next-gen wireless system design Policy Trump administration debates Chinese cellular module ban in FCC crackdown expansion Chips TSMC allocates $20bn to Arizona expansion amid water, labor challenges Funding Isomorphic Labs raises $2.1bn, becoming DeepMind's biggest spinout investment Breaking Sam Altman to Testify in OpenAI Governance Trial as Musk Suit Proceeds Breaking Jensen Huang excluded from Trump's China delegation amid US-China export tensions Breaking Amazon employees admit to artificially inflating AI tool adoption to meet internal metrics Market Tech firm CGI appoints new CEO after AI-driven share price decline Chips Apple-Intel Foundry Deal Could Reshape U.S. Chip Manufacturing Chips AI tools accelerate DRC closure for complex SoC design and verification Market Macron pledges $27 billion Africa investment push amid geopolitical competition Breaking NVIDIA partners SAP on specialized enterprise agents for business processes Market Morning briefing: Nadella testimony, GM layoffs, China trade negotiations top market agenda Market AI Mania Pulls Old-Guard Industrials Into Chip-Stock Volatility Breaking Mistral AI, TanStack npm packages compromised in 'mini Shai Hulud' supply-chain malware campaign Market eBay rejects GameStop's $56B takeover bid as "neither credible nor attractive" Breaking AI-assisted bug hunting collapses 90-day vulnerability disclosure window Market Wall Street deploys blockchain for $13 trillion repo market; JPMorgan leads settlement acceleration Chips NASA partners with Microchip to build space-grade chips with 100x power for lunar/Mars missions Funding SoftBank injects $450M into British AI chip company Graphcore Chips Error Vector Magnitude emerges as critical metric for next-gen wireless system design

Funding Tuesday, May 12, 2026 at 02:46 PM

Isomorphic Labs raises $2.1bn, becoming DeepMind's biggest spinout investment

Isomorphic Labs, the drug discovery AI spinout backed by DeepMind parent Alphabet, has closed a $2.1 billion Series B round, valuing the company at over $10 billion. The raise caps rapid growth since launch in 2023, signaling investor confidence in AI-driven pharma.

For enterprise teams, the round underscores the startup-to-scale velocity in deep-tech AI: a two-year-old company with a niche TAM (drug discovery) is now commanding top-tier unicorn pricing. It reflects broader appetite for applied AI in R&D workflows.

Read at source →